StockNews.AI
ADIL
StockNews.AI
13 days

Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting

1. Adial completes successful FDA End of Phase 2 meeting for AD04. 2. FDA supports Phase 3 clinical trial design for AD04 targeting Alcohol Use Disorder. 3. Regulatory feedback improves potential partnerships and funding opportunities for Adial. 4. AD04 shows promise in treating AUD and other addiction disorders. 5. Positive FDA meeting enhances collaboration prospects with potential partners.

8m saved
Insight
Article

FAQ

Why Bullish?

The successful FDA meeting suggests positive momentum for AD04, potentially boosting investor confidence. Previous FDA guidance often correlates with stock price increases, as seen with other biotech companies.

How important is it?

The FDA's endorsement signifies important regulatory validation, likely increasing the company's value and interest from investors and partners.

Why Short Term?

The immediate positive feedback can quickly translate to increased investor interest and stock price movement, particularly as clinical development progresses.

Related Companies

VRTXAVEOPTCT
August 06, 2025 08:00 ET  | Source: Adial Pharmaceuticals, Inc Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the completion of a successful End of Phase 2 meeting (EOP2M) with the Food and Drug Administration (FDA). The FDA has provided input into the AD04 Phase 3 adaptive design clinical trial and the overall clinical program. Following the meeting, Adial is now prepared to advance AD04- its lead investigational drug and a serotonin-3 receptor antagonist- into its Phase 3 clinical development program for the treatment of Alcohol Use Disorder (AUD) in individuals with heavy drinking and select genotypes and, most importantly, the AG+ genotype. The objective for the EOP2M was to align with the FDA on the design of the Phase 3 clinical development program for AD04. This included key elements of the planned adaptive study design elements, such as population, endpoints, inclusion/exclusion criteria, dose regime, and affirmation of the biomarker positive and biomarker negative groups.    Clarity and validation from the FDA on the clinical development path is expected to strengthen Adial’s position in discussions with potential partners, who typically view regulatory momentum as a key de-risking milestone in the decision-making process. Cary Claiborne, President and Chief Executive Officer of Adial commented, “We are highly encouraged by the FDA’s feedback and progress made over the past several months, which included a thorough analysis of our historical data through advanced statistical analytics and simulation modeling. These efforts have been instrumental in refining the trial design to focus on the AUD population most likely to benefit from AD04 treatment. We look forward to advancing the clinical program for AD04 and are optimistic about achieving a successful outcome in the Phase 3 program. Importantly, we believe the productive FDA meeting will also enhance our ability to advance ongoing partnership discussions, as regulatory clarity is a key consideration for potential collaborators.” About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com. Forward-Looking Statements This communication contains certain “forward-looking statements” within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding conducting strategic partnership discussions following the positive FDA meeting, advancing AD04 into its Phase 3 clinical development program for the treatment of AUD in individuals with heavy drinking and select genotypes, including the AG+ genotype, clarity and validation from the FDA on the clinical development path strengthening Adial’s position in discussions with potential partners, refining the trial design to focus on the AUD population most likely to benefit from AD04 treatment, achieving a successful outcome in the Phase 3 program and the potential of AD04 to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law. Contact: Crescendo Communications, LLC David Waldman / Alexandra Schilt Tel: 212-671-1020 Email: adil@crescendo-ir.com

Related News